An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

MUSCAT: The National Programme for Early Detection of Diabetic Retinopathy using artificial intelligence (AI) technologies ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025.

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

In an era where chronic diseases are reshaping global health priorities, the diabetic retinopathy market stands out as a ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Eye floaters, those drifting spots in your vision, are often harmless but can signal hypertension or diabetes. High blood ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye ...